PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included ...
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...
In contrast to an oral presentation ... When you finish designing your poster, save a copy as an image file (JPG or PNG), a PDF, or a Slide Deck (Google Slides or PowerPoint). Your choice of file type ...
TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. The US Food and Drug Administration has cleared Tyra's Investigational New Drug application to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback